The impact on overall survival (OS) of first-line gefitinib (G) and erlotinib (E) and of clinical factors in advanced non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor mutations (EGFR mut) based on meta-analysis of 1,231 patients (pts) enrolled in 6 major randomized trials.

臺大醫院-腫瘤醫學部;臺大醫學院-腫瘤醫學研究所;臺大醫學院-癌症研究中心;Lee, CheeCheeLeeDavies, Lucy ClaireLucy ClaireDaviesWu, Yi-LongYi-LongWuMitsudomi, TetsuyaTetsuyaMitsudomiInoue, AkiraAkiraInoueRosell, RafaelRafaelRosellZhou, CaicunCaicunZhouNakagawa, KazuhikoKazuhikoNakagawaThrongprasert, SumitraSumitraThrongprasertFukuoka, MasahiroMasahiroFukuokaGralla, Richard J.Richard J.GrallaGebski, ValValGebskiMok, TonyTonyMokYang, James Chih-HsinJames Chih-HsinYang2017-06-272018-07-092017-06-272018-07-092015http://ntur.lib.ntu.edu.tw//handle/246246/280131[SDGs]SDG3The impact on overall survival (OS) of first-line gefitinib (G) and erlotinib (E) and of clinical factors in advanced non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor mutations (EGFR mut) based on meta-analysis of 1,231 patients (pts) enrolled in 6 major randomized trials.